Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295497 | 1.00 | HRH3 (0.59) | HRH3CYP3A4TSHRMAPK1SLC18A3 | |
| SCHEMBL4301730 | 0.90 | HRH3 (0.73) | HRH3CYP3A4TSHRMAPK1SLC18A3 | |
| SCHEMBL4301735 | 0.90 | HRH3 (0.73) | HRH3CYP3A4TSHRMAPK1SLC18A3 | |
| SCHEMBL7025858 | 0.90 | HRH3 (0.73) | HRH3CYP3A4TSHRMAPK1SLC18A3 | |
| SCHEMBL4301727 | 0.90 | HRH3 (0.73) | HRH3CYP3A4TSHRMAPK1SLC18A3 | |
| SCHEMBL13660548 | 0.84 | HRH3 (0.82) | HRH3MEN1MAPTKMT2A | |
| SCHEMBL4297369 | 0.84 | HRH3 (0.82) | HRH3MEN1MAPTKMT2A | |
| SCHEMBL4300745 | 0.80 | HRH3 (0.90) | HRH3OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL4295473 | 0.80 | HRH3 (0.53) | HRH3MAPK1SLC18A3MEN1MAPT | |
| SCHEMBL13660549 | 0.80 | HRH3 (0.53) | HRH3MAPK1SLC18A3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | HRH3 7/4885CYP3A4 439/4885TSHR 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.